Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Lukáš Smolej"'
Autor:
Alice Sýkorová, František Folber, Kamila Polgárová, Heidi Móciková, Juraj Ďuraš, Kateřina Steinerová, Aleš Obr, Adriana Heindorfer, Miriam Ladická, Ľubica Lukáčová, Erika Čellárová, Ivana Plameňová, David Belada, Andrea Janíková, Marek Trněný, Tereza Jančárková, Vít Procházka, Andrej Vranovský, Margaréta Králiková, Jan Vydra, Lukáš Smolej, Ľuboš Drgoňa, Martin Sedmina, Eva Čermáková, Robert Pytlík
Publikováno v:
Cancer Medicine, Vol 13, Iss 17, Pp n/a-n/a (2024)
Abstract Aim The aim of this study was to analyse the outcomes of patients with large B‐cell lymphoma (LBCL) treated with chimeric antigen receptor T‐cell therapy (CAR‐Tx), with a focus on outcomes after CAR T‐cell failure, and to define the
Externí odkaz:
https://doaj.org/article/613627563fa145bcad4718e937c66eed
Autor:
Pavel Vodárek, Dominika Écsiová, Vladimíra Řezáčová, Ondřej Souček, Martin Šimkovič, Doris Vokurková, David Belada, Pavel Žák, Lukáš Smolej
Publikováno v:
Cancer Medicine, Vol 13, Iss 15, Pp n/a-n/a (2024)
Abstract Introduction The impact of chemoimmunotherapy (CIT) on immunoglobulin (Ig) quantities in patients with chronic lymphocytic leukemia (CLL) has not been extensively studied. Methods We analyzed Ig levels in 45 stable patients with indolent CLL
Externí odkaz:
https://doaj.org/article/ab5ccf42e2684a0aabf0f605607b37be
Autor:
Pavel Vodárek, Dominika Écsiová, Vladimíra Řezáčová, Ondřej Souček, Martin Šimkovič, Doris Vokurková, David Belada, Pavel Žák, Lukáš Smolej
Publikováno v:
Cancer Medicine, Vol 12, Iss 6, Pp 6956-6970 (2023)
Abstract Background In chronic lymphocytic leukemia (CLL), changes in the peripheral blood lymphocyte subsets play an important role in disease progression and infectious complications. The impact of chemoimmunotherapy (CIT) on these changes has not
Externí odkaz:
https://doaj.org/article/2422169dc87b49f79bc7174866fc2304
Autor:
Alexander Egle, Thomas Melchardt, Petra Obrtlíková, Lukáš Smolej, Tomáš Kozák, Michael Steurer, Johannes Andel, Sonja Burgstaller, Eva Mikušková, Liana Gercheva, Thomas Nösslinger, Tomáš Papajík, Miriam Ladická, Michael Girschikofsky, Mikuláš Hrubiško, Ulrich Jäger, Daniela Voskova, Martin Pecherstorfer, Eva Králiková, Christina Burcoveanu, Emil Spasov, Andreas Petzer, Georgi Mihaylov, Julian Raynov, Horst Oexle, August Zabernigg, Emília Flochová, Stanislav Palášthy, Olga Stehlíková, Michael Doubek, Petra Altenhofer, Lukas Weiss, Teresa Magnes, Lisa Pleyer, Anton Klingler, Jiří Mayer, Richard Greil
Publikováno v:
Cancer Medicine, Vol 8, Iss 4, Pp 1401-1405 (2019)
Abstract No data are available regarding obesity and outcome in Chronic Lymphocytic Leukemia (CLL). We analyzed 263 patients from the AGMT CLL‐8a Mabtenance trial for the impact of obesity. The trial included patients after rituximab‐containing i
Externí odkaz:
https://doaj.org/article/5fbc792402b144bb941d23c116493c05
Autor:
Lukáš Smolej
Publikováno v:
Acta Medica, Vol 53, Iss 4, Pp 213-220 (2010)
Treatment of chronic lymphocytic leukemia (CLL) has recently undergone several major changes. Most importantly, large randomized trials (CLL-8 in first line and REACH in relapse) clearly demonstrated superiority of chemoimmunotherapy consisting of fl
Externí odkaz:
https://doaj.org/article/8f26a7dc2dd74840983d5a0498a457c4
Autor:
Vladimíra Vroblová, Lukáš Smolej, Filip Vrbacký, Karolína Jankovičová, Monika Hrudková, Jaroslav Malý, Jan Krejsek
Publikováno v:
Acta Medica, Vol 52, Iss 1, Pp 3-8 (2009)
Chronic lymphocytic leukemia (CLL) is the most frequent leukemic disease of adults in the Western world. It is remarkable by an extraordinary heterogeneity of clinical course with overall survival ranging from several months to more than 15 years. Cl
Externí odkaz:
https://doaj.org/article/926d8e02cbf94abba4e4fb2be37d3415
Autor:
David Belada, Lukáš Smolej, Monika Hrudková, Pavla Štěpánková, Alice Sýkorová, Pavel Žák, Jiří Bukač, Jaroslav Malý
Publikováno v:
Acta Medica, Vol 50, Iss 2, Pp 113-118 (2007)
CHOP chemotherapy has been used as a standard first-line treatment for diffuse large B-cell lymphoma since the 1970s. Phase III trials have shown that the addition of rituximab (R) to CHOP chemotherapy leads to significant improvements in response ra
Externí odkaz:
https://doaj.org/article/a241a4edf82d4e8c934cd5c849f37879
Autor:
Martin Šimkovič, Peter Turcsányi, Martin Špaček, Jana Mihályová, Pavlína Ryznerová, Mária Maco, Pavel Vodárek, Dominika Écsiová, Hynek Poul, Heidi Móciková, Jana Zuchnická, Anna Panovská, Mohammad Lekaa, Martina Oršulová, Adéla Prchlíková, Lukáš Stejskal, Stanislava Mašlejová, Yvona Brychtová, Lucie Bezděková, Tomáš Papajík, Daniel Lysák, Marek Trněný, Lukáš Smolej, Michael Doubek
Publikováno v:
Annals of Hematology. 102:811-817
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1496132ae0478a61b3f7a6279fb40b28
https://doi.org/10.1007/s00277-023-05147-z
https://doi.org/10.1007/s00277-023-05147-z
Autor:
Pavel Vodárek, Dominika Écsiová, Vladimíra Řezáčová, Ondřej Souček, Martin Šimkovič, Doris Vokurková, David Belada, Pavel Žák, Lukáš Smolej
Publikováno v:
Cancer Medicine. 12:6956-6970
In chronic lymphocytic leukemia (CLL), changes in the peripheral blood lymphocyte subsets play an important role in disease progression and infectious complications. The impact of chemoimmunotherapy (CIT) on these changes has not been extensively stu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e2db80f9e274168ea5b69551dc911d8f
https://doi.org/10.1002/cam4.5492
https://doi.org/10.1002/cam4.5492
Autor:
Dominika Écsiová, Pavel Vodárek, Petra Rozsívalová, Filip Vrbacký, Kateřina Hrochová, Petr Hoffmann, Pavel Žák, Lukáš Smolej, Martin Šimkovič
Publikováno v:
Onkologie. 16:151-154
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c9da282e6dcf81ec37412d1f9fc87554
https://doi.org/10.36290/xon.2022.029
https://doi.org/10.36290/xon.2022.029